[48] Therefore, in the 'real-world' setting it does not appear that many 'straightforward' candidates for mitral valve surgery are being referred for MitraClip. Nonetheless, even in this very sick ...

Life became increasingly difficult for those patients who were facing chronic heart problems. Mitral valve leakage or regurgitation is the most common valvular heart disease. With a global ...

Mitraclip is a groundbreaking procedure transforming cardiac care by treating mitral valve regurgitation. This minimally invasive treatment offers new hope for patients with heart conditions. Listen ...

The MitraClip is a single-size clip device that has been used to treat patients with functional, mixed and degenerative MR. The Clip has a dual arm structure, with grippers above the arms to ...

目前来看，在瓣膜赛道，企业管线里还有大量研发产品有待商业化上市。以国内发展最为成熟的主动脉瓣膜为例，截至目前，国内已有超过10款经导管主动脉瓣膜产品获批，既有跨国企业爱德华和美敦力的产品，也有来自启明医疗、沛嘉医疗、心通医疗和杰成医疗等本土企业的产品。上述四家本土企业占据了国内约80%的TAVR植入量份额。

In the trial, which included patients with significant, symptomatic MR (3+ or 4+) randomized to TEER with Pascal or MitraClip (Abbott), there was no significant difference in MR reduction, quality of ...

Objectives This study evaluates the 5-year clinical outcomes of transcatheter mitral valve (MV) repair with the MitraClip device in patients at high risk for MV surgery treated in the Endovascular ...

Transcatheter edge‐to‐edge repair of the mitral valve (mTEER) reduced a hierarchical end point that included death and heart failure hospitalization in COAPT (Cardiovascular Outcomes Assessment of the ...

Dr. Mehmet Oz, affectionately known by his stage name, Dr. Oz, is probably one of the most recognizable doctors in the United ...

The Forttuna Global Excellence Awards 2024, held on December 6-7 aboard the iconic Queen Elizabeth 2 cruise in Dubai, ...

周五，TD Cowen对雅培实验室（NYSE:ABT）股票表示信心，将公司目标价从之前的130美元上调至135美元，同时维持买入评级。 此次调整是在雅培成功在美国推出TriClip后做出的，这是雅培医疗设备组合的重要补充。根据InvestingPro的公允价值分析，雅培目前市值1950亿美元，市盈率为34.2，估值似乎合理。 雅培实验室最近完成了其雄心勃勃的计划，推出了公司称之为"超级五星"的产品 ...